Referenser till artikeln Parkinsonspatient på bättringsvägen
av Hanne Koplev

1) Aarhus privatklinik for holistisk medicin, <>
2) <>
3) Meara, Jolyon et al. ”Accuracy of diagnosis in patients with presumed Parkinson's disease.” Age and Ageing, Vol. 28, March 1999, pp. 99-02. <>
4) <> <>
5) Montgomery EB Jr, ”Heavy metals and the etiology of Parkinson's disease and other movement disorders.” Toxicology. 1995-03-31;97(1-3):3-9. <;db=PubMed&amp;list_uids=7716790&amp;dopt=Abstract> 6) Thiruchelvam, Mona et al. ”The Nigrostriatal Dopaminergic System as a Preferential Target of Repeated Exposures to Combined Paraquat and Maneb: Implications for Parkinson's Disease.” J Neuroscience, 2000-12-15, 20(24):9207-9214. <>
7) ”Parkinson's Disease Research at NIEHS” ,
8)Godfrey ME, , Wojcik DP, Krone CA. Apolipoprotein E genotyping as a potential biomarker for mercury neurotoxicity. J Alzheimers Dis. 2003 Jun;5(3):189-95.

Referenser till artikeln Glutationterapi vid Parkinsons
av Helene Sandström

1) Perlmutter, David. ”New Advances in Parkinson's Disease.” Townsend Letter for Doctors and Patients, juli 2001.
2) ”Glutathione Therapy.” En intervju med David Perlmutter av Jill Selby.
3) <>
4) Klinghardt, Dietrich: Intervju med Dr Joseph Mercola, juni 2008. Tillgänglig via
5) Lewis, P.A.W., Klinghardt, D., Michel, J. ”Orally administered L-Glutation Therapy for Parkinsons patients.” 2002-05-23. Ej publicerad.
6) Wang, H., Kuo, M.”Pyridoxine sometimes fails to be activated to pyridoxal phosphate.” Brain Research Bulletin, sept 2002, vol 58, nr 6:541
5) Klinghardt, Dietrich. ”A Comprehensive Review of Heavy Metal Detoxification and Clinical Pearls from 30 Years of Medical Practice.”
6) Katzenschlager R, Evans A et al. ”Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study.” J Neurol Neurosurg Psychiatry. 2004 Dec;75(12):1672-7.
7) Derksen, Ann. “Some ways to reduce toxin exposure for your child.”
8) Manyam, Bala V. et al. ”Neuroprotective effects of the antiparkinson drug Mucuna pruriens.” Phytother Res. 2004 Sep;18(9):706-12.

Referenser till artikeln Parkinsons sjukdom
Mats Hansson

Benshlomo, Y, Whitehead, AS, Smith, GD: ”Parkinson's, Alzheimer's, and motor neurone disease - Clinical and pathological overlap may suggest common genetic and environmental factors.” British Medical Journal; 312 (7033) p724 Mar 23 1996
Chaturvedi, S, Ostbye, T, Stoessl, AJ, Merskey, H, Hachinski,V: ”Environmental exposures in elderly Canadians with Parkinson's disease.” Canadian Journal of Neurological Sciences; 22 (3) 232-234 aug 1995
Finkelstein, Y, Vardi, J, Kesten, MM & Hod, I: ”The enigma of parkinsonism in chronic borderline mercury intoxication, resolved by challenge with penicillamine.” Neurotoxicol 17 1996 291-296
Goldsmith, JR et al: ”Clustering of Parkinson's disease points to environmental etiology.” Arch Env Hlth 45 1990 88
Jenner, P, Dexter, DT, Sian, J, Schapira, AHV, Marsden, CD: ”Oxidative Stress as a Cause of Nigral Cell Death in Parkinson's Disease and Incidental Lewy Body Disease.” Annals of Neurology; 32 p S82-S87 1992
Jenner, P: ”Altered Mitochondrial Function, Iron Metabolism and Glutathione Levels in Parkinson's Disease.” Acta Neurologica Scandinavica; 87 p 6-13 1993
Mizuno,Y et al: ”Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease.” Biochem Biophys Res Comm 163 1989 1450
Montastruc, JL, LIau, ME, Rascol, 0, Senard, JM: ”Druginduced parkinsonism: A review.” Fundamental & Clinical Pharmacology; 8 (4) p 293-306 1994
Morens, DM, Grandinetti, A, Reed, D, White, LR: ”Smoking-Associated Protection from Alzheimers and Parkinsons Disease.” Lancet; 343 (8893) p 356-357 Feb 5 1994
Ngim, C-H & Devathasan, G: ”Epidemiologic study on the association between body burden mercury level and idiopathic Parkinson's disease.” Neuroepidemiol 8 1989 128-141
Perry, TL et al: ”Alphatocopherol and betacarotene do not protect marmosets against the dopaminergic neurotoxicity of N-methyl-4-phenyl- 1 ,2,3,6-tetrahydropyridine.” J Neurol Sci 8l 1987 321
Rybicki, BA et al: ”Parkinson's disease mortality and the industrial use of heavy metals in Michigan.” Movement Disord 8 1993 87-92
Schulz, JB, Henshaw, DR, Matthews, RT, Beal, MF: ”Coenzyme Q(l0) and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity.” Experimental Neurology; 132 (2) p 279-283 Apr 1995
Seidler, A, Hellenbrand, W, Robra, BP, Vieregge, P, Nischan, P, Joerg, J, Oertel, WIT, Ulm, G, Schneider, E: ”Possible environmental, occupational, and other etiologic factors for Parkinson's disease: A casecontrol study in Germany.” Neurology; 46(5) p 1275-1284 May 1996 (BH37)
Simonian, NA, Coyle, JT:”Oxidative stress in neurodegenerative diseases.” Annual Review of Pharmacology and Toxicology; 36 p 83-106 1996
Vizuete, ML, Steffen, V, Machado, A, Cano, J: ”1-Methyl-4-Phenylpyridinium Has Greater Neurotoxic Effect After Selenium Deficiency Than After Vitamin E Deficiency in Rat Stratium.” European Journal of Pharmacology -Environmental Toxicology and Pharmacology Section; 270 (2-3) p 183-l87Apr 4 1994
Wagner, GC et al: ”Ascorbic acid reduces the dopamine depletion induced by MPTP.” Neuropharmacol 24 1985 1261
Wang,WZ, Fang, XH, Cheng, XM, Jiang, DH, Lin, ZJA: ”Case-Control Study on the Environmental Risk Factors of Parkinson's Disease in Tianjin, China.” Neuroepidemiology; 12 (4) p 209-218 Jul-aug 1993
Björklund, G: ”Parkinsons sykdom, kvikksolv og andre tungmetaller.” Tidsskr Nor Laegeforen, 1995 Feb 28; 115(6):757.
Zhang, ZX, Roman, GC: Worldwide Occurrence of Parkinson's Disease - An Updated Review. Neuroepidemiology; 12 (4) p195-208 Jul-aug 1993